CSPC PHARMA (01093) announced that the indacaterol/mometasone powder for inhalation developed by the group has received approval from China's National Medical Products Administration to commence clinical trials in China. The product is intended for the maintenance treatment of asthma in adults and adolescents aged 12 and above. Indacaterol is a long-acting beta-2 agonist (LABA) that works by relaxing smooth muscles and dilating the bronchi. Mometasone furoate is an inhaled corticosteroid (ICS) that provides local anti-inflammatory effects. The indacaterol/mometasone inhalation powder is the first twice-daily inhaled ICS-LABA combination product included in China's National Reimbursement Drug List (2022 edition), offering a more efficient and convenient treatment option for asthma patients. Furthermore, the approval for clinical trials of this product represents another significant achievement for the group's advanced innovative inhalation technology platform and establishes a solid foundation for the development of subsequent inhaled formulations in the pipeline.